Premium
Risankizumab vs. adalimumab for moderate‐to‐severe plaque psoriasis: a critical appraisal
Author(s) -
AlJanabi A.,
Warren R.B.
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18856
Subject(s) - adalimumab , psoriasis , medicine , plaque psoriasis , dermatology , critical appraisal , alternative medicine , pathology , disease